{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:10:59Z","timestamp":1794345059335,"version":"4.9.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Israel Cancer Association grant","award":["20240079"],"award-info":[{"award-number":["20240079"]}],"id":[{"id":"https:\/\/ror.org\/03yxd7304","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This studBreast Cancer Research Foundation","award":["BCRF-095"],"award-info":[{"award-number":["BCRF-095"]}],"id":[{"id":"https:\/\/ror.org\/0348ff195","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Israeli Cancer Association Hereditary Breast Consortium"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Isr J Health Policy Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The implementation of Israeli National screening for\n                      <jats:italic>BRCA1\/BRCA2<\/jats:italic>\n                      pathogenic variants (PVs) in 2020 has led to a significant increase in the number of unaffected female carriers who are referred to high-risk surveillance clinics (HRSCs). Lack of standardization in protocols for risk reduction and surveillance between HRSCs results in confusion and gaps in care. We aimed to identify discrepancies in existing practices and lead to policy development of a national policy for surveillance, management and risk reducing strategies in\n                      <jats:italic>BRCA-PV<\/jats:italic>\n                      carriers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comparative analysis of risk reduction and surveillance protocols of the nine leading HRSCs across Israel, comprising the Israeli Consortium for hereditary breast and ovarian cancer (HBOC), and multi-center meetings to develop consensus guidelines for HRSCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our analysis revealed a high level of prior consensus on critical aspects including risk-reducing mastectomy, salpingo-oophorectomy, fertility treatment, contraception, hormone replacement therapy, and general health behavior. For breast cancer (BC) imaging surveillance there was variability regarding frequency (e.g. only one HRSC offers biannual MRI for\n                      <jats:italic>BRCA1<\/jats:italic>\n                      carriers), age limits (five centers continue in women older than 75 years), frequency during pregnancy and lactation (four HRSCs every three months and four others every six months; one does not recommend any surveillance), and surveillance post-mastectomy. For ovarian cancer (OvCa) surveillance, there was also variability: six centers recommend biannual\/annual serum CA-125 level and pelvic sonography for all women, one center recommends this for all women till risk-reducing-bilateral-salpingo-oophorectomy (RRBSO), and two centers exclusively for women from age 35 till RRBSO. Surveillance recommendations for malignancies other than BC and OvCa differed greatly among centers.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13584-026-00746-3","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:02:06Z","timestamp":1769727726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing healthcare for female BRCA carriers in the population screening era: developing a harmonized national policy for surveillance and risk-reduction"],"prefix":"10.1186","volume":"15","author":[{"given":"Rachel","family":"Michaelson-Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunit","family":"Armon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naama","family":"Srebnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat Koller","family":"Volkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pnina","family":"Mor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gekhtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ora","family":"Rosengarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi Maisel","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Goldvaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahelli","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana Madorsky","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinat Bernstein","family":"Molho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miri Sklair","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbal","family":"Kedar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Raz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Simchoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviad","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miora","family":"Linial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat","family":"Carmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbar","family":"Gatot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Braha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakefet Chen","family":"Shtoyerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikma","family":"Mordechai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth E.","family":"Half","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohar","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon Bratman","family":"Morag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanir M.","family":"Allweis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephrat","family":"Levy-Lahad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"746_CR1","unstructured":"Workbook. DeathCauses [Internet]. [cited 2024 Oct 8]. Available from: https:\/\/statistics.health.gov.il\/views\/DeathCauses\/Mortalityratedetailedcauses?%3Aembed=y&Language%20Desc=English"},{"issue":"3","key":"746_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"746_CR3","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA - Journal of the American Medical Association [Internet]. 2017 Jun 20 [cited 2021 Feb 18];317(23):2402\u201316. Available from: https:\/\/jamanetwork.com\/"},{"key":"746_CR4","doi-asserted-by":"crossref","unstructured":"Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet [Internet]. 1996 [cited 2025 May 2];14(2):185\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8841191\/","DOI":"10.1038\/ng1096-185"},{"key":"746_CR5","doi-asserted-by":"crossref","unstructured":"King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science [Internet]. 2003 Oct 24 [cited 2024 Oct 8];302(5645):643\u20136. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/14576434\/","DOI":"10.1126\/science.1088759"},{"key":"746_CR6","doi-asserted-by":"crossref","unstructured":"Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T, Gershoni R et al. Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel. Gynecol Oncol [Internet]. 2003 Jun 1 [cited 2024 Oct 8];89(3):494\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12798717\/","DOI":"10.1016\/S0090-8258(03)00152-5"},{"key":"746_CR7","doi-asserted-by":"crossref","unstructured":"Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet [Internet]. 2000 [cited 2024 Oct 8];66(4):1259\u201372. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10739756\/","DOI":"10.1086\/302853"},{"key":"746_CR8","doi-asserted-by":"crossref","unstructured":"Kotsopoulos J, Gronwald J, Huzarski T, M\u00f8ller P, Pal T, McCuaig JM et al. Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncol [Internet]. 2024 Apr 18 [cited 2024 Jun 21];10(4):484\u201392. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38421677\/","DOI":"10.1001\/jamaoncol.2023.6937"},{"key":"746_CR9","unstructured":"Dwyer M. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae) Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. 2026 [cited 2025 Jul 24]; Available from: https:\/\/www.nccn.org\/home\/member-"},{"key":"746_CR10","doi-asserted-by":"crossref","unstructured":"Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genetics in Medicine [Internet]. 2015 Jan 1 [cited 2023 Nov 20];17(1):70\u201387. Available from: http:\/\/www.gimjournal.org\/article\/S1098360021049182\/fulltext","DOI":"10.1038\/gim.2014.147"},{"key":"746_CR11","doi-asserted-by":"crossref","unstructured":"Michaelson-Cohen R, Cohen MJ, Cohen C, Greenberg D, Shmueli A, Lieberman S et al. Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies. Cancers (Basel) [Internet]. 2022 Dec 1 [cited 2023 Nov 21];14(24). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36551598\/","DOI":"10.3390\/cancers14246113"},{"key":"746_CR12","doi-asserted-by":"crossref","unstructured":"Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. J Natl Cancer Inst [Internet]. 2014 Jan 1 [cited 2024 Aug 2];107(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25435542\/","DOI":"10.1093\/jnci\/dju380"},{"key":"746_CR13","unstructured":"Ministry of Health Medical. Technologies Supplement a 2020 [Internet]. [cited 2025 Jan 16]. Available from: https:\/\/www.gov.il\/BlobFolder\/policy\/mk03-2020\/he\/files_circulars_mk_mk03_2020.pdf"},{"key":"746_CR14","unstructured":"IMAJ | The Israel Medicine Association Journal | Volume 25, Number, 1. January 2023 | Variations in Practice and Geographic Disparities Between Dedicated Multidisciplinary Clinics for BRCA1\/BRCA2 Mutation Carriers in Israel [Internet]. [cited 2024 Oct 6]. Available from: https:\/\/www.ima.org.il\/MedicineIMAJ\/viewarticle.aspx?year=2023&month=01&page=18. https:\/\/pubmed.ncbi.nlm.nih.gov\/36718731\/"},{"key":"746_CR15","doi-asserted-by":"crossref","unstructured":"Sessa C, Balma\u00f1a J, Bober SL, Cardoso MJ, Colombo N, Curigliano G et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol [Internet]. 2023 Jan 1 [cited 2024 Oct 10];34(1):33\u201347. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36307055\/","DOI":"10.1016\/j.annonc.2022.10.004"},{"key":"746_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers14194592","volume":"14","author":"R Bernstein-Molho","year":"2022","unstructured":"Bernstein-Molho R, Friedman E, Evron E. Controversies and open questions in management of Cancer-Free carriers of germline pathogenic variants in BRCA1\/BRCA2. Cancers (Basel). 2022;14:19.","journal-title":"Cancers (Basel)"},{"key":"746_CR17","doi-asserted-by":"crossref","unstructured":"Matan LS, Perri T, Kogan L, Brandt B, Meyer R, Levin G. Ovarian cancer risk management in BRCA-mutation carriers: A comparison of six international and national guidelines. Eur J Obstet Gynecol Reprod Biol [Internet]. 2022 Nov 1 [cited 2024 Oct 8];278:166\u201371. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36208522\/","DOI":"10.1016\/j.ejogrb.2022.09.035"},{"issue":"9","key":"746_CR18","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jacr.2023.04.002","volume":"20","author":"DL Monticciolo","year":"2023","unstructured":"Monticciolo DL, Newell MS, Moy L, Lee CS, Destounis SV. Breast cancer screening for women at higher-than-average risk: updated recommendations from the ACR. J Am Coll Radiol. 2023;20(9):902\u201314.","journal-title":"J Am Coll Radiol"},{"key":"746_CR19","doi-asserted-by":"crossref","unstructured":"Di Maria S, van Nijnatten TJA, Jeukens CRLPN, Vedantham S, Dietzel M, Vaz P. Understanding the risk of ionizing radiation in breast imaging: Concepts and quantities, clinical importance, and future directions. Eur J Radiol [Internet]. 2024 Dec 1 [cited 2025 Apr 30];181:111784. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0720048X2400500X","DOI":"10.1016\/j.ejrad.2024.111784"},{"issue":"1","key":"746_CR20","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s00330-023-10281-3","volume":"34","author":"AJ van der Molen","year":"2024","unstructured":"van der Molen AJ, Quattrocchi CC, Mallio CA, Dekkers IA, European Society of Magnetic Resonance in Medicine BGREC (ESMRMB G. Ten years of gadolinium retention and deposition: ESMRMB-GREC looks backward and forward. Eur Radiol. 2024;34(1):600\u201311.","journal-title":"Eur Radiol"},{"issue":"2","key":"746_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10549-020-05759-3","volume":"183","author":"KD Whitaker","year":"2020","unstructured":"Whitaker KD, Sheth D, Olopade OI. Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet? Breast Cancer Res Treat. 2020;183(2):243\u201350.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"746_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1037\/hea0000156","volume":"34","author":"DB Portnoy","year":"2015","unstructured":"Portnoy DB, Loud JT, Han PKJ, Mai PL, Greene MH. Effects of false-positive cancer screenings and cancer worry on risk-reducing surgery among BRCA1\/2 carriers. Health Psychol. 2015;34(7):709\u201317.","journal-title":"Health Psychol"},{"issue":"9","key":"746_CR23","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jamaoncol.2020.2922","volume":"6","author":"HA Geuzinge","year":"2020","unstructured":"Geuzinge HA, Obdeijn IM, Rutgers EJT, Saadatmand S, Mann RM, Oosterwijk JC, et al. Cost-effectiveness of breast cancer screening with magnetic resonance imaging for women at Familial risk. JAMA Oncol. 2020;6(9):1381\u20139.","journal-title":"JAMA Oncol"},{"issue":"4","key":"746_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamaoncol.2023.6944","volume":"10","author":"J Lubinski","year":"2024","unstructured":"Lubinski J, Kotsopoulos J, Moller P, Pal T, Eisen A, Peck L, et al. MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol. 2024;10(4):493.","journal-title":"JAMA Oncol"},{"key":"746_CR25","doi-asserted-by":"publisher","first-page":"110310","DOI":"10.1016\/j.clinimag.2024.110310","volume":"116","author":"H Bufman","year":"2024","unstructured":"Bufman H, Sorin V, Faermann R, Bernstein-Molho R, Friedman E, Barash Y, et al. Clinical experience on the limited role of ultrasound for breast cancer screening in BRCA1 and BRCA2 mutations carriers aged 30\u201339 years. Clin Imaging. 2024;116:110310.","journal-title":"Clin Imaging"},{"issue":"6","key":"746_CR26","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1158\/1078-0432.CCR-18-0200","volume":"25","author":"RSC Guindalini","year":"2019","unstructured":"Guindalini RSC, Zheng Y, Abe H, Whitaker K, Yoshimatsu TF, Walsh T, et al. Intensive surveillance with biannual dynamic Contrast-Enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers. Clin Cancer Res. 2019;25(6):1786\u201394.","journal-title":"Clin Cancer Res"},{"issue":"39","key":"746_CR27","doi-asserted-by":"publisher","first-page":"14205","DOI":"10.1073\/pnas.1415979111","volume":"111","author":"E Gabai-Kapara","year":"2014","unstructured":"Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A. 2014;111(39):14205\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"746_CR28","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/ijc.21273","volume":"117","author":"CA Cullinane","year":"2005","unstructured":"Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1\/BRCA2 mutation carriers. Int J Cancer. 2005;117(6):988\u201391.","journal-title":"Int J Cancer"},{"issue":"2","key":"746_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.acra.2022.03.030","volume":"30","author":"R Faermann","year":"2023","unstructured":"Faermann R, Friedman E, Kaidar-Person O, Brodsky M, Neiman OH, Shalmon A, et al. Pregnancy associated breast cancer among Israeli BRCA1\/BRCA2 carriers in a high-risk clinic. Acad Radiol. 2023;30(2):248\u201354.","journal-title":"Acad Radiol"},{"issue":"2","key":"746_CR30","doi-asserted-by":"publisher","first-page":"R42","DOI":"10.1186\/bcr3138","volume":"14","author":"J Kotsopoulos","year":"2012","unstructured":"Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, Foulkes WD, et al. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2012;14(2):R42.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"746_CR31","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ygyno.2020.09.037","volume":"159","author":"J Kotsopoulos","year":"2020","unstructured":"Kotsopoulos J, Gronwald J, McCuaig JM, Karlan BY, Eisen A, Tung N, et al. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2020;159(3):820\u20136.","journal-title":"Gynecol Oncol"},{"key":"746_CR32","doi-asserted-by":"crossref","unstructured":"Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA - Journal of the American Medical Association [Internet]. 2016 Sep 6 [cited 2025 Apr 30];316(9):952\u201361. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27599330\/","DOI":"10.1001\/jama.2016.12126"},{"key":"746_CR33","doi-asserted-by":"publisher","unstructured":"Nissan N, Bauer E, Moss Massasa EE, Sklair-Levy M. Breast MRI during pregnancy and lactation: clinical challenges and technical advances. Insights into Imaging 2022 13:1 [Internet]. 2022 Apr 9 [cited 2025 Apr 30];13(1):1\u201321. Available from: https:\/\/insightsimaging.springeropen.com\/articles\/https:\/\/doi.org\/10.1186\/s13244-022-01214-7","DOI":"10.1186\/s13244-022-01214-7"},{"key":"746_CR34","doi-asserted-by":"publisher","unstructured":"Nissan N, Gluskin J, Ochoa-Albiztegui RE, Fruchtman-Brot H, Sung JS, Jochelson MS. Performance of breast MRI for high-risk screening during lactation. Eur Radiol. 2025;35(5):2366\u20132375. https:\/\/doi.org\/10.1007\/s00330-024-11091-x","DOI":"10.1007\/s00330-024-11091-x"},{"key":"746_CR35","doi-asserted-by":"crossref","unstructured":"Woitek R, Pfeiler G, Farr A, Kapetas P, Furtner J, Bernathova M et al. MRI-based quantification of residual fibroglandular tissue of the breast after conservative mastectomies. Eur J Radiol [Internet]. 2018 Jul 1 [cited 2025 Apr 30];104:1\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29857853\/","DOI":"10.1016\/j.ejrad.2018.04.028"},{"key":"746_CR36","doi-asserted-by":"crossref","unstructured":"Marcinkute R, Woodward ER, Gandhi A, Howell S, Crosbie EJ, Wissely J et al. Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers. J Med Genet [Internet]. 2022 Feb 1 [cited 2024 Oct 10];59(2):133\u201340. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33568438\/","DOI":"10.1136\/jmedgenet-2020-107356"},{"key":"746_CR37","unstructured":"Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AIM, Coll\u00e9e M, Meijers-Heijboer HEJ et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat [Internet]. 2019 Oct 1 [cited 2025 May 1];177(3):723\u201333. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31302855\/"},{"key":"746_CR38","doi-asserted-by":"crossref","unstructured":"Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database of Systematic Reviews [Internet]. 2018 Apr 5 [cited 2025 May 1];2018(4). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29620792\/","DOI":"10.1002\/14651858.CD002748.pub4"},{"issue":"5","key":"746_CR39","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jmig.2020.11.023","volume":"28","author":"E Matanes","year":"2021","unstructured":"Matanes E, Volodarsky-Perel A, Eisenberg N, Rottenstreich M, Yasmeen A, Mitric C, et al. Endometrial cancer in germline BRCA mutation carriers: a systematic review and meta-analysis. J Minim Invasive Gynecol. 2021;28(5):947\u201356.","journal-title":"J Minim Invasive Gynecol"},{"key":"746_CR40","doi-asserted-by":"crossref","unstructured":"De Jonge MM, De Kroon CD, Jenner DJ, Oosting J, De Hullu JA, Mourits MJE et al. Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study. J Natl Cancer Inst [Internet]. 2021 Sep 1 [cited 2024 Sep 17];113(9):1203\u201311. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33710348\/","DOI":"10.1093\/jnci\/djab036"},{"issue":"5","key":"746_CR41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/cncr.31842","volume":"125","author":"Y Laitman","year":"2019","unstructured":"Laitman Y, Michaelson-Cohen R, Levi E, Chen-Shtoyerman R, Reish O, Josefsberg Ben-Yehoshua S, et al. Uterine cancer in Jewish Israeli BRCA1\/2 mutation carriers. Cancer. 2019;125(5):698\u2013703.","journal-title":"Cancer"},{"key":"746_CR42","doi-asserted-by":"crossref","unstructured":"Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst [Internet]. 2002 Sep 18 [cited 2024 Sep 17];94(18):1358\u201365. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12237281\/","DOI":"10.1093\/jnci\/94.18.1358"},{"key":"746_CR43","unstructured":"Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA et al. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncol [Internet]. 2016 Nov 1 [cited 2024 Sep 17];2(11):1434\u201340. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27367496\/"},{"key":"746_CR44","doi-asserted-by":"crossref","unstructured":"Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol [Internet]. 2013 Jul [cited 2024 Sep 17];130(1):127\u201331. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23562522\/","DOI":"10.1016\/j.ygyno.2013.03.027"},{"issue":"1","key":"746_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ygyno.2006.08.004","volume":"104","author":"ME Beiner","year":"2007","unstructured":"Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol. 2007;104(1):7\u201310.","journal-title":"Gynecol Oncol"},{"key":"746_CR46","doi-asserted-by":"crossref","unstructured":"Trabert B, Bauer DC, Buist DSM, Cauley JA, Falk RT, Geczik AM et al. Association of Circulating Progesterone With Breast Cancer Risk Among Postmenopausal Women. JAMA Netw Open [Internet]. 2020 Apr 1 [cited 2025 May 1];3(4):e203645\u2013e203645. Available from: https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2764844","DOI":"10.1001\/jamanetworkopen.2020.3645"},{"key":"746_CR47","doi-asserted-by":"crossref","unstructured":"Andy C, Nerattini M, Jett S, Carlton C, Zarate C, Boneu C et al. Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition. Front Endocrinol (Lausanne) [Internet]. 2024 [cited 2025 May 1];15. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38501109\/","DOI":"10.3389\/fendo.2024.1350318"},{"key":"746_CR48","doi-asserted-by":"crossref","unstructured":"Michaelson-Cohen R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A et al. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Eur J Cancer [Internet]. 2021 May 1 [cited 2025 Nov 6];148:95\u2013102. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33743487\/","DOI":"10.1016\/j.ejca.2021.02.007"},{"key":"746_CR49","doi-asserted-by":"crossref","unstructured":"Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P et al. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncol [Internet]. 2018 Aug 1 [cited 2024 Sep 17];4(8):1059\u201365. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29710224\/","DOI":"10.1001\/jamaoncol.2018.0211"},{"issue":"1","key":"746_CR50","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/AOG.0000000000002414","volume":"131","author":"JMK Wong","year":"2018","unstructured":"Wong JMK, Bortoletto P, Tolentino J, Jung MJ, Milad MP. Urinary tract injury in gynecologic laparoscopy for benign indication: a systematic review. Obstet Gynecol. 2018;131(1):100\u20138.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"746_CR51","doi-asserted-by":"publisher","first-page":"e4901","DOI":"10.1016\/j.ajog.2013.06.018","volume":"209","author":"AG Lake","year":"2013","unstructured":"Lake AG, McPencow AM, Dick-Biascoechea MA, Martin DK, Erekson EA. Surgical site infection after hysterectomy. Am J Obstet Gynecol. 2013;209(5):e4901\u20139.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"746_CR52","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/ijgc-2023-004801","volume":"34","author":"C Nahshon","year":"2024","unstructured":"Nahshon C, Segev Y, Schmidt M, Lavie O. Attitude of BRCA1\/2 mutation carriers towards surgical risk reduction for breast, ovarian and uterine cancer: still much to be done. Int J Gynecol Cancer. 2024;34(2):260\u20136.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"746_CR53","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","volume":"8","author":"SI Labidi-Galy","year":"2017","unstructured":"Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8(1):1093.","journal-title":"Nat Commun"},{"issue":"3","key":"746_CR54","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/AOG.0000000000001592","volume":"128","author":"EC Evans","year":"2016","unstructured":"Evans EC, Matteson KA, Orejuela FJ, Alperin M, Balk EM, El-Nashar S, et al. Salpingo-oophorectomy at the time of benign hysterectomy: a systematic review. Obstet Gynecol. 2016;128(3):476\u201385.","journal-title":"Obstet Gynecol"},{"key":"746_CR55","doi-asserted-by":"publisher","unstructured":"Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Lubinski J et al. ARTICLE International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer [Internet]. 2019;10:15\u201321. Available from: https:\/\/doi.org\/10.1038\/s41416-019-0446-1","DOI":"10.1038\/s41416-019-0446-1"},{"key":"746_CR56","doi-asserted-by":"crossref","unstructured":"Zadabedini Masouleh T, Etchegary H, Hodgkinson K, Wilson BJ, Dawson L. Beyond Sterilization: A Comprehensive Review on the Safety and Efficacy of Opportunistic Salpingectomy as a Preventative Strategy for Ovarian Cancer. Current Oncology. 2023, Vol 30, Pages 10152\u201310165 [Internet]. 2023 Nov 28 [cited 2024 Oct 6];30(12):10152\u201365. Available from: https:\/\/www.mdpi.com\/1718-7729\/30\/12\/739\/htm","DOI":"10.3390\/curroncol30120739"},{"issue":"11","key":"746_CR57","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1001\/jamasurg.2023.4164","volume":"158","author":"RM Kahn","year":"2023","unstructured":"Kahn RM, Gordhandas S, Godwin K, Stone RL, Worley MJ, Lu KH, et al. Salpingectomy for the primary prevention of ovarian cancer: A systematic review. JAMA Surg. 2023;158(11):1204\u201311.","journal-title":"JAMA Surg"},{"key":"746_CR58","doi-asserted-by":"crossref","unstructured":"Gaba F, Blyuss O, Chandrasekaran D, Osman M, Goyal S, Gan C et al. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. BJOG [Internet]. 2021 Mar 1 [cited 2024 Oct 6];128(4):714\u201326. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32803845\/","DOI":"10.1111\/1471-0528.16424"},{"key":"746_CR59","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ygyno.2023.04.006","volume":"173","author":"L Perez","year":"2023","unstructured":"Perez L, Webster E, Bull L, Brewer JT, Ahsan MD, Lin J, et al. Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: a systematic review of the literature. Gynecol Oncol. 2023;173:106\u201313.","journal-title":"Gynecol Oncol"},{"key":"746_CR60","doi-asserted-by":"crossref","unstructured":"Steenbeek MP, Harmsen MG, Hoogerbrugge N, De Jong MA, Maas AHEM, Prins JB et al. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1\/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial. JAMA Oncol [Internet]. 2021 Aug 1 [cited 2024 Oct 6];7(8):1203\u201312. Available from: https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2780476","DOI":"10.1001\/jamaoncol.2021.1590"},{"key":"746_CR61","doi-asserted-by":"crossref","unstructured":"Menon U, Gentry-Maharaj A, Burnell M, Ryan A, Kalsi JK, Singh N et al. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial. Health Technol Assess [Internet]. 2023 May [cited 2024 Jun 11];1. Available from: \/pmc\/articles\/PMC10542866\/","DOI":"10.3310\/BHBR5832"},{"issue":"2","key":"746_CR62","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ygyno.2019.08.034","volume":"155","author":"J Gronwald","year":"2019","unstructured":"Gronwald J, Lubinski J, Huzarski T, Cybulski C, Menkiszak J, Sio\u0142ek M, et al. A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy. Gynecol Oncol. 2019;155(2):270\u20134.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"746_CR63","doi-asserted-by":"publisher","first-page":"e251435","DOI":"10.1001\/jamanetworkopen.2025.1435","volume":"8","author":"S Armon","year":"2025","unstructured":"Armon S, Hollander A, Segev Y, Rosengarten O, Tomer A, Levy-Lahad E, et al. Presymptomatic awareness of BRCA1\/BRCA2 status and outcomes in women with ovarian cancer. JAMA Netw Open. 2025;8(3):e251435.","journal-title":"JAMA Netw Open"},{"key":"746_CR64","doi-asserted-by":"publisher","unstructured":"Rosenthal AN, Fraser LSM, Philpott S, Manchanda R, Burnell M, Badman P et al. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. J Clin Oncol [Internet]. 2017 May 1 [cited 2019 Apr 18];35(13):1411\u201320. Available from: https:\/\/doi.org\/10.1200\/JCO.2016.69.9330","DOI":"10.1200\/JCO.2016.69.9330"},{"issue":"11","key":"746_CR65","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/jnci\/djae151","volume":"116","author":"SA Narod","year":"2024","unstructured":"Narod SA, Gronwald J, Karlan B, Moller P, Huzarski T, Tung N, et al. Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2024;116(11):1753\u201360.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"746_CR66","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13048-019-0525-1","volume":"12","author":"PI Stanciu","year":"2019","unstructured":"Stanciu PI, Ind TEJ, Barton DPJ, Butler JB, Vroobel KM, Attygalle AD, et al. Development of peritoneal carcinoma in women diagnosed with serous tubal intraepithelial carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO). J Ovarian Res. 2019;12(1):50.","journal-title":"J Ovarian Res"},{"issue":"5","key":"746_CR67","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/cncr.31211","volume":"124","author":"MG Harmsen","year":"2018","unstructured":"Harmsen MG, Piek JMJ, Bulten J, Casey MJ, Rebbeck TR, Mourits MJ, et al. Peritoneal carcinomatosis after risk-reducing surgery in BRCA1\/2 mutation carriers. Cancer. 2018;124(5):952\u20139.","journal-title":"Cancer"},{"issue":"14","key":"746_CR68","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00003","volume":"40","author":"S Lieberman","year":"2022","unstructured":"Lieberman S, Goldvaser H, Levy-Lahad E. Germline pathogenic variants in BRCA1 and BRCA2: malignancies beyond female breast and ovarian cancers. J Clin Oncol. 2022;40(14):1590\u20134.","journal-title":"J Clin Oncol"},{"issue":"14","key":"746_CR69","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.21.02112","volume":"40","author":"S Li","year":"2022","unstructured":"Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40(14):1529\u201341.","journal-title":"J Clin Oncol"},{"issue":"5","key":"746_CR70","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.gie.2021.12.001","volume":"95","author":"MS Sawhney","year":"2022","unstructured":"Sawhney MS, Calderwood AH, Thosani NC, Rebbeck TR, Wani S, Canto MI, et al. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc. 2022;95(5):817\u201326.","journal-title":"Gastrointest Endosc"},{"issue":"2","key":"746_CR71","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/cncr.35052","volume":"130","author":"I Laish","year":"2024","unstructured":"Laish I, Schechter M, Dancour A, Lieberman S, Levi Z, Goldberg Y, et al. The benefit of pancreatic cancer surveillance in carriers of germline BRCA1\/2 pathogenic variants. Cancer. 2024;130(2):256\u201366.","journal-title":"Cancer"},{"issue":"3","key":"746_CR72","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1053\/j.gastro.2018.05.035","volume":"155","author":"MI Canto","year":"2018","unstructured":"Canto MI, Almario JA, Schulick RD, Yeo CJ, Klein A, Blackford A, et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology. 2018;155(3):740-751.e2.","journal-title":"Gastroenterology"},{"issue":"17","key":"746_CR73","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1200\/JCO.2015.64.0730","volume":"34","author":"H Vasen","year":"2016","unstructured":"Vasen H, Ibrahim I, Ponce CG, Slater EP, Matth\u00e4i E, Carrato A, et al. Benefit of surveillance for pancreatic cancer in High-Risk individuals: outcome of Long-Term prospective Follow-Up studies from three European expert centers. J Clin Oncol. 2016;34(17):2010\u20139.","journal-title":"J Clin Oncol"},{"key":"746_CR74","doi-asserted-by":"publisher","unstructured":"Usui Y, Taniyama Y, Endo M, Koyanagi YN, Kasugai Y, Oze I et al. Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer. New England Journal of Medicine [Internet]. 2023 Mar 30 [cited 2025 Jun 1];388(13):1181\u201390. Available from: https:\/\/www.nejm.org\/doi\/pdf\/https:\/\/doi.org\/10.1056\/NEJMoa2211807","DOI":"10.1056\/NEJMoa2211807"},{"issue":"2","key":"746_CR75","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1053\/j.gastro.2018.04.026","volume":"155","author":"X Zhang","year":"2018","unstructured":"Zhang X, Li M, Chen S, Hu J, Guo Q, Liu R, et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review. Gastroenterology. 2018;155(2):347-354.e9.","journal-title":"Gastroenterology"},{"issue":"11","key":"746_CR76","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/jnci\/djy148","volume":"110","author":"M Oh","year":"2018","unstructured":"Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, et al. BRCA1 and BRCA2 gene mutations and colorectal cancer risk: systematic review and Meta-analysis. J Natl Cancer Inst. 2018;110(11):1178\u201389.","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"746_CR77","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"Breast Cancer Linkage Consortium","year":"1999","unstructured":"Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310\u20136.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"746_CR78","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10689-011-9506-2","volume":"11","author":"A Moran","year":"2012","unstructured":"Moran A, O\u2019Hara C, Khan S, Shack L, Woodward E, Maher ER, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer. 2012;11(2):235\u201342.","journal-title":"Fam Cancer"},{"key":"746_CR79","unstructured":"Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA - Journal of the American Medical Association [Internet]. 2015 Apr 7 [cited 2025 May 2];313(13):1347\u201361. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25849179\/"},{"key":"746_CR80","doi-asserted-by":"crossref","unstructured":"Liu C, Crew KD, Morse J, Linder JE, Antoniou AC, Carver T et al. Implementing integrated genomic risk assessments for breast cancer: lessons learned from the Electronic Medical Records and Genomics study. JAMIA Open [Internet]. 2025 Sep 2 [cited 2025 Nov 6];8(5). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/41140463\/","DOI":"10.1093\/jamiaopen\/ooaf113"},{"key":"746_CR81","doi-asserted-by":"crossref","unstructured":"Shang H, Ding Y, Venkateswaran V, Boulier K, Kathuria-Prakash N, Malidarreh PB et al. Generalizability of PGS313 for breast cancer risk in a Los Angeles biobank. Human Genetics and Genomics Advances [Internet]. 2024 Jul 18 [cited 2025 Nov 6];5(3). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38704641\/","DOI":"10.1016\/j.xhgg.2024.100302"},{"key":"746_CR82","doi-asserted-by":"crossref","unstructured":"Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genetics in Medicine [Internet]. 2019 Aug 1 [cited 2025 Nov 6];21(8):1708\u201318. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30643217\/","DOI":"10.1038\/s41436-018-0406-9"},{"key":"746_CR83","doi-asserted-by":"crossref","unstructured":"Carver T, Hartley S, Lee A, Cunningham AP, Archer S, de Villiers CB et al. CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. Cancer Epidemiol Biomarkers Prev [Internet]. 2021 Mar 1 [cited 2025 Nov 6];30(3):469\u201373. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33335023\/","DOI":"10.1158\/1055-9965.EPI-20-1319"},{"key":"746_CR84","doi-asserted-by":"crossref","unstructured":"Oblak T, \u0160kerl P, Narang BJ, Blagus R, Krajc M, Novakovi\u0107 S et al. Breast cancer risk prediction using Tyrer-Cuzick algorithm with an 18-SNPs polygenic risk score in a European population with below-average breast cancer incidence. Breast [Internet]. 2023 Dec 1 [cited 2025 Nov 6];72. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37857130\/","DOI":"10.1016\/j.breast.2023.103590"},{"key":"746_CR85","doi-asserted-by":"crossref","unstructured":"Pesapane F, Nicosia L, D\u2019Amelio L, Quercioli G, Pannarale MR, Priolo F et al. Artificial Intelligence-Driven Personalization in Breast Cancer Screening: From Population Models to Individualized Protocols. Cancers (Basel) [Internet]. 2025 Sep 1 [cited 2025 Nov 6];17(17). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40940998\/","DOI":"10.3390\/cancers17172901"},{"key":"746_CR86","doi-asserted-by":"crossref","unstructured":"Grisolia P, Tufano R, Iannarone C, De Falco A, Carlino F, Graziano C et al. Differential methylation of circulating free DNA assessed through cfMeDiP as a new tool for breast cancer diagnosis and detection of BRCA1\/2 mutation. J Transl Med [Internet]. 2024 Dec 1 [cited 2025 Nov 6];22(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39407254\/","DOI":"10.1186\/s12967-024-05734-2"},{"key":"746_CR87","doi-asserted-by":"crossref","unstructured":"Bernstein-Molho R, Friedman E, Evron E. Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1\/BRCA2. Cancers (Basel) [Internet]. 2022 Oct 1 [cited 2025 Nov 6];14(19). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36230512\/","DOI":"10.3390\/cancers14194592"}],"container-title":["Israel Journal of Health Policy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13584-026-00746-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13584-026-00746-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13584-026-00746-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:42:31Z","timestamp":1794339751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13584-026-00746-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["746"],"URL":"https:\/\/doi.org\/10.1186\/s13584-026-00746-3","relation":{},"ISSN":["2045-4015"],"issn-type":[{"value":"2045-4015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to correct the funding section.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"4"}}